rethinkPeptides Search
Menu
Study breakdown

Peptides in Breast Cancer: From Tumor-Targeting to Drug Delivery and Immunotherapy

ReviewModerate evidence
The takeaway

Review of peptides in breast cancer therapy covers tumor-targeting peptides, peptide-drug conjugates, antimicrobial peptides, and emerging peptide-based drug delivery systems.

Key finding

Review of peptides in breast cancer therapy covers tumor-targeting peptides, peptide-drug conjugates

What the researchers found

Review of peptides in breast cancer therapy covers tumor-targeting peptides, peptide-drug conjugates, antimicrobial peptides, and emerging peptide-based drug delivery systems.

Why it matters

This finding has implications for the millions of patients using or considering peptide-based therapies.

The numbers in context

Review article covering multiple peptide applications — specific data from individual studies referenced within.

How the study worked

Clinical or preclinical study with methodology detailed in the full publication.

Who was studied

Review covering breast cancer research across preclinical and clinical studies

What this study cannot tell us

Study-specific limitations are discussed in the full publication. As with all research, findings should be interpreted in the context of study design and population.

How to read the evidence

Evidence grade assessment based on study design and methodology detailed in the full publication.

When this study was published

Published in 2025. Reflects current state of peptide therapeutic research.

The bigger picture

This study adds to the rapidly expanding evidence base for peptide-based therapeutics across multiple medical specialties.

Questions still open

  • What are the long-term implications of these findings?
  • How do these results compare to other studies in this area?
  • What further research is needed to confirm and extend these findings?

Common questions

What does this study mean for patients?
Review of peptides in breast cancer therapy covers tumor-targeting peptides, peptide-drug conjugates, antimicrobial peptides, and emerging peptide-based drug delivery systems.
How reliable are these findings?
The evidence level depends on study design. Clinical trials provide stronger evidence than case reports. Consult the full publication and discuss with your healthcare provider.

Read the original research

Peptides in breast cancer therapy: From mechanisms to emerging drug delivery and immunotherapy strategies.

Pathology, research and practice, 269, 155946

Citation

Alaei, Elmira; Hashemi, Farid; Farahani, Najma; Tahmasebi, Safa; Nabavi, Noushin; Daneshi, Salman; Mahmoodieh, Behnaz; Rahimzadeh, Payman; Taheriazam, Afshin; Hashemi, Mehrdad. (2025). Peptides in breast cancer therapy: From mechanisms to emerging drug delivery and immunotherapy strategies.. Pathology, research and practice, 269, 155946. https://doi.org/10.1016/j.prp.2025.155946